Description
Premium GHRP-2 & Mod GRF 1-29 Blend for Sale | 30mg Each per Vial | ≥99% Purity | 48-Hour Delivery Across EU & UK
GHRP-2 + Mod GRF 1-29: The Synergistic Growth Hormone Secretagogue Blend for Comprehensive Research
https://eupeptidelap.co.uk/ is proud to present the GHRP-2 30mg + Mod GRF 1-29 30mg peptide blend, a premium research-grade combination of two extensively studied growth hormone secretagogues manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with this synergistic blend for sale that delivers exceptional purity, consistency, and documented quality .
This dual-peptide research blend combines GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin or KP-102), a synthetic hexapeptide belonging to the growth hormone secretagogue receptor (GHSR) family, with Mod GRF 1-29 (also known as CJC-1295 without DAC), a synthetic analog of growth hormone-releasing hormone (GHRH) . Each vial contains 30mg of each peptide, supplied as a lyophilized solid to maintain long-term stability and integrity. HPLC-verified at ≥99% purity with full Certificates of Analysis provided, this blend is widely studied in laboratory models of growth hormone signaling, endocrine regulation, tissue repair pathways, and metabolic research.
GHRP-2 is a hexapeptide that acts as a potent growth hormone secretagogue receptor agonist. Research indicates that GHRP-2 demonstrates approximately 10-fold greater potency than earlier generations of GH-releasing peptides such as GHRP-6 and GHRP-1 when tested in the same experimental systems . Unlike GHRP-6, GHRP-2 has been shown to increase intracellular cAMP concentrations in somatotroph cells, operating through signaling pathways similar to those activated by growth hormone-releasing factor (GRF) . This unique mechanistic profile makes GHRP-2 an invaluable tool for researchers investigating distinct pathways in pituitary somatotroph function.
Mod GRF 1-29 (Modified Growth Hormone Releasing Factor 1-29) is a truncated analog of endogenous GHRH, consisting of the first 29 amino acids of the native hormone—a sequence that retains full biological activity for stimulating growth hormone release. Scientists have found that the complete biological activity of GHRH is contained within this 29-amino acid sequence. The structural modifications, in which four amino acids are replaced, appear to increase its resistance to enzymatic degradation, allowing for more impactful receptor engagement and longevity within experimental systems . This enhanced stability may support sustained stimulation of growth hormone release over a prolonged period in research settings.
Findings suggest that GHRP-2 combined with Mod GRF 1-29 may increase growth hormone release and improve results above either peptide alone . When coadministered at maximal doses, an additive effect on GH release has been observed . This blend is used in preclinical research designs focused on comparative analysis of GHRH receptor versus GHSR-1a receptor activation, characterization of pulsatile endocrine signaling patterns, and investigation of growth hormone axis feedback regulation.
For researchers seeking to buy peptide online EU for investigations into growth hormone dynamics, tissue regeneration, metabolic regulation, or endocrine function, eupeptidelap.co.uk offers this premium blend with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.
The Scientific Foundation of the GHRP-2 + Mod GRF 1-29 Blend
Distinct Yet Complementary Mechanisms of Action
The GHRP-2 and Mod GRF 1-29 blend represents a strategic combination of two peptides that target distinct receptors within the growth hormone axis through partially overlapping intracellular signaling pathways, potentially offering additive effects that surpass what either peptide might achieve alone .
Mod GRF 1-29: GHRH Receptor Activation via cAMP Pathway
Mod GRF 1-29 is designed to mimic the signaling properties of endogenous growth hormone-releasing hormone (GHRH). It selectively binds to GHRH receptors located on somatotroph cells in the anterior pituitary gland . Upon binding, it activates G-proteins associated with the inner surface of the cell membrane, leading to the production of cyclic adenosine monophosphate (cAMP) as a secondary messenger. Elevated cAMP levels activate protein kinases that phosphorylate target proteins, influencing gene expression for increased growth hormone synthesis.
One proposed pathway that Mod GRF 1-29 may activate involves the enzyme adenylyl cyclase. This enzyme converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The rise in cAMP levels may activate protein kinase A (PKA), an enzyme that adds phosphate groups to various cellular proteins. PKA-mediated phosphorylation may modify voltage-dependent calcium channels on the cell membrane, potentially triggering secretory vesicle release from pituitary cells.
GHRP-2: GHSR Activation via cAMP-Dependent Pathway
GHRP-2 operates through a mechanism that shares features with both GHRP-6 and GRF signaling pathways. Unlike GHRP-6, which stimulates GH release without increasing intracellular cAMP levels, GHRP-2 has been shown to increase cAMP concentrations in somatotroph cells in a manner similar to GRF . In partially purified sheep somatotrophs, GHRP-2 increased intracellular cAMP concentrations and caused GH release in a dose-dependent manner .
When GHRP-2 binds to GHS-R1a receptors on pituitary cells, it may induce a conformational change that activates multiple intracellular signaling pathways. Research indicates that GHRP-2 may influence calcium channel modulation, cAMP pathway activation, and protein kinase C signaling . Studies using the cAMP antagonist Rp-cAMP have demonstrated that blocking cAMP signaling prevents GH release in response to both GHRP-2 and GRF .
Receptor Pharmacology and Selectivity
Research has revealed important distinctions in receptor pharmacology between GHRP-2 and other GHRP family members. An antagonist for the GRF receptor, [Ac-Tyr1,D-Arg2]-GRF 1-29, significantly diminishes the effect of GHRP-2 and GRF on cAMP accumulation and GH release, but does not affect GH release induced by GHRP-6 . This finding suggests that while GHRP-6 operates through receptors distinct from the GHRH receptor, GHRP-2 may engage signaling pathways that interact more directly with GHRH receptor-mediated mechanisms.
The effect of maximal doses of GHRP-2 (100 nM) on GH release can be totally abolished by the GRF receptor antagonist, further supporting the concept that GHRP-2 acts through a different receptor mechanism than earlier generations of GH-releasing peptides . This unique pharmacological profile makes GHRP-2 particularly valuable for comparative studies of growth hormone secretagogue signaling.
Additive and Synergistic Potential
The differences in how each peptide interacts with pituitary cells have led researchers to hypothesize that using both compounds simultaneously may yield additive effects on growth hormone secretion. When GRF and GHRP-2 are coadministered at maximal doses, an additive effect on release of GH is obtained . Furthermore, combined treatment with GRF and GHRP-2 results in additive effects on both cAMP accumulation and GH levels .
This additive effect may stem from the convergence of signaling pathways. GHRP-2 appears to enhance the somatotroph’s responsiveness to GHRH stimulation, potentially through interactions between their respective signaling cascades. The dual activation of growth hormone release pathways makes this blend particularly valuable for researchers studying the complex regulation of the GH axis.
Desensitization and Recovery Studies
Understanding the temporal dynamics of peptide action is crucial for designing experimental protocols. Research demonstrates that the response to a second application of GHRP-2 given within one hour of initial application is significantly lower than the response to the first application, indicating homologous desensitization . However, when GHRP-2 is applied first and GRF is given one hour later, the second response is not attenuated, indicating no cross-desensitization between GHRP-2 and GRF responses .
These findings provide valuable information for designing dosing intervals in chronic studies and suggest that the two peptides act through pathways that can be independently regulated.
Key Research Applications
Growth Hormone Signaling and Pituitary Research
The GHRP-2 and Mod GRF 1-29 blend is extensively used in studies investigating growth hormone dynamics, pituitary function, and endocrine regulation . The complementary mechanisms of these peptides provide researchers with a sophisticated tool for exploring:
-
Receptor-Specific Signaling: Investigate how GHRH and GHSR pathways activate distinct intracellular signaling cascades, with GHRP-2 increasing cAMP levels in a manner similar to GRF while GHRP-6 does not
-
Additive Interactions: Study how combined receptor activation produces additive effects on GH release beyond single-peptide responses
-
Hypothalamic-Pituitary Axis: Explore feedback mechanisms and hormonal regulation at the pituitary level, including potential actions on the arcuate nucleus
-
Desensitization Studies: Investigate homologous desensitization patterns and the absence of cross-desensitization between GHRP-2 and GRF pathways
Appetite and Metabolic Research
Studies have examined the potential impacts of GHRP-2 on hunger hormone signaling and its relationship to growth hormone secretion. In controlled clinical research, a cohort of research models was divided into experimental and control groups, with one group receiving a peptide compound and the other receiving saline solution over five hours . Reports suggest that the peptide-introduced group displayed a 35% increase in food consumption compared to the saline group, normalized based on body mass, suggesting a notable potential of the peptide on hunger hormone regulation .
Additionally, research models introduced to the peptides displayed a significant rise in circulating growth hormone levels relative to the control group. These findings may imply that the peptide blend may influence both appetite control and growth hormone release, warranting further exploration into its underlying mechanisms and potential research implications in the field of appetite modulation and growth hormone regulation .
Growth Regulation and Metabolic Modulation
Recent clinical research has studied the efficacy of growth hormone secretagogues (GHSs) and growth hormone-releasing peptides (GHRPs) within controlled research environments. Upon analyzing the data, researchers observed that introducing the peptide possibly corresponded with several physiological impacts :
-
In non-mature populations, an increase in linear growth rates was reported, aligning with the peptides’ potential role in supporting developmental growth pathways
-
Among mature models, peptides appeared to correlate with an increase in lean muscular tissue mass, better-supported appetite regulation, and possible metabolic support that may favor muscle cell anabolism
-
For models with higher BMI, the introduction of GHSs and GHRPs appeared to indicate promising reductions in bone turnover rates and more regulated sleep patterns, potentially indicating broader metabolic impacts beyond growth hormone modulation
Existing findings suggest that GHSs and GHRPs may “increase lean mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, support muscular tissue strength, and support linear growth” .
Age-Related Endocrine Research
In controlled clinical studies, researchers have explored the impacts of growth hormone-releasing peptides on several hormone levels, specifically examining growth hormone (GH), cortisol, prolactin, and adrenocorticotropic hormone (ACTH) in male subjects across two distinct cellular age groups . Based on the results, both groups had increased circulating growth hormone levels following peptide introduction; however, a statistically significant rise was observed in the younger group compared to the matured models, suggesting possible age-dependent variability in the peptide’s efficacy on GH release .
Additionally, the peptides appeared to indirectly stimulate ACTH and cortisol levels in both cellular age groups, although the elevation was more pronounced in the juvenile models. A mild increase in prolactin levels was also reported, suggesting that the peptides may engage multiple hormonal pathways .
Tissue Regeneration and Cellular Repair Research
One of the intriguing areas of research involving the GHRP-2 and Mod GRF 1-29 blend is its relevance in tissue repair and regenerative cell studies . Given that growth hormone is considered to play a role in cellular proliferation and protein synthesis, researchers have theorized that these peptides might impact regenerative responses in various types of tissue. In vitro models suggest that enhanced GH levels may encourage cellular differentiation and proliferation, potentially accelerating tissue repair.
The blend may be explored for its possible impact on myogenesis or the formation of muscle tissue as part of regenerative studies. Growth hormone signaling has been linked to satellite cell activation, an essential process in muscle repair and regeneration. Research indicates that the GHRP-2 and Mod GRF 1-29 combination may increase the availability of GH in a controlled manner, which may, in theory, improve outcomes in tissue cultures investigating muscle regeneration and cellular repair mechanisms .
Cellular Metabolism and Adipose Tissue Research
Research indicates that the GHRP-2 and Mod GRF 1-29 blend might also hold promise in metabolic research, where their impact on energy balance and nutrient utilization can provide insights into cellular metabolism . GH influences several metabolic pathways, including lipolysis, protein synthesis, and carbohydrate metabolism. By modulating GH levels, the blend might theoretically allow researchers to explore metabolic processes in greater depth.
Studies exploring adipogenesis have hypothesized that GH may influence the breakdown of lipids as a cellular energy source. This may provide insights into metabolic research on energy utilization and lipid dynamics. Furthermore, investigations suggest that GHRP-2’s ghrelin-like receptor interactions might add a secondary layer of impact on metabolic pathways involved in hunger signaling and energy storage . This dual interaction may be of interest in studies seeking to better understand how metabolic signaling might be regulated through peptide pathways.
Cognitive and Neural Research
Although GH is traditionally associated with physical growth processes, recent research suggests that it may have potential roles in cognitive and neural science . GH receptors are found in brain tissue, including regions such as the hippocampus, which is associated with memory and learning. Studies purport that GH may support neurogenesis—the formation of new neurons—and support synaptic plasticity, potentially influencing cognitive function.
Findings imply that the GHRP-2 and Mod GRF 1-29 blend may serve as a tool for probing neuroendocrine processes related to cognition. Its potential to modulate GH pathways in cellular environments might provide researchers with a model for investigating GH’s impact on neural integrity. By examining peptide influences on neural plasticity and cellular resilience, scientists might gain a deeper understanding of how GH-related pathways support brain function, especially in response to environmental challenges or stressors .
Quality Assurance: Setting the Standard for Research Compounds
Manufacturing Excellence
eupeptidelap.co.uk sources the GHRP-2 + Mod GRF 1-29 blend from certified GMP facilities with rigorous quality control protocols:
-
HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography
-
Mass Spectrometry Verification: Molecular weight confirmation via LC-HRMS
-
Batch-Specific Certificates of Analysis: Complete documentation for each production run
-
Precisely Blended: Each vial contains exactly 30mg of GHRP-2 and 30mg of Mod GRF 1-29, quality-controlled for accurate composition
Chemical and Product Specifications
| Specification | Detail |
|---|---|
| Product Name | GHRP-2 30mg + Mod GRF 1-29 30mg Blend |
| Blend Composition | GHRP-2 30mg, Mod GRF 1-29 30mg per vial |
| Form | Lyophilized solid (freeze-dried powder) |
| Purity | ≥99% (HPLC verified) |
Mod GRF 1-29 Specifications :
| Property | Value |
|---|---|
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | 3367.9 g/mol |
| Amino Acid Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
GHRP-2 Specifications :
| Property | Value |
|---|---|
| CAS Number | 158861-67-7 (Pralmorelin) |
| Molecular Formula | C₄₅H₅₅N₉O₆ |
| Molecular Weight | 817.98 g/mol |
| Amino Acid Sequence | D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂ |
| Specification | Detail |
|---|---|
| Storage | Store at −20°C in a dry, dark environment |
| Shipping | Ambient temperature with protective packaging |
| Intended Use | Research and laboratory use only |
| Documentation | Certificate of Analysis provided with each batch |
Stability and Handling
Lyophilized Form: The peptides are supplied as a lyophilized solid to ensure long-term stability and integrity. Lyophilization is a unique dehydration process where the peptides are frozen and then subjected to low pressure, causing water to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure.
Storage Recommendations: Once peptides have been received, it is imperative that they are kept cold and away from light. For short-term use, refrigeration under 4°C is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more. However, for longer-term storage (several months to years), it is preferable to store peptides in a freezer at -20°C or -80°C .
Reconstitution: Reconstitute using bacteriostatic water or another suitable solvent according to your research protocol. Gentle swirling—not shaking—is recommended to dissolve the powder completely. Once reconstituted, peptides must be stored in the refrigerator to maintain stability and will typically remain stable for up to 30 days .
Key Benefits
-
Premium Quality Manufacturing: GMP-certified production with rigorous quality control, ≥99% HPLC-verified purity
-
Synergistic Blend: Combines GHRH analog (Mod GRF 1-29) with GHSR agonist (GHRP-2) for complementary pathway activation
-
High Concentration: 30mg each per vial—substantial quantity for extended research studies
-
Distinct Signaling Pathways: GHRP-2 increases cAMP levels similar to GRF, unlike GHRP-6 which does not affect cAMP
-
Greater Potency: GHRP-2 demonstrates approximately 10-fold greater potency than earlier generation GHRPs
-
Additive GH Release: Coadministration of GRF and GHRP-2 produces additive effects on GH release
-
No Cross-Desensitization: GHRP-2 and GRF responses show no cross-desensitization, allowing for independent pathway investigation
-
Appetite Research Applications: Studies demonstrate 35% increase in food consumption in peptide-introduced models
-
Metabolic Research: Investigate lipolysis, protein synthesis, and carbohydrate metabolism pathways
-
Tissue Regeneration Studies: Research potential impacts on myogenesis and cellular repair mechanisms
-
Age-Related Endocrine Research: Study age-dependent variability in GH response and hormone pathway engagement
-
Bone Density Studies: Research bone turnover rates and metabolic impacts in higher BMI models
-
Sleep Pattern Research: Investigate connections between GH axis and sleep regulation
-
Cognitive Research: Explore GH receptor distribution in hippocampal regions and neurogenesis
-
Receptor Selectivity: GRF receptor antagonist abolishes GHRP-2 effect but not GHRP-6 effect
-
Comprehensive Documentation: Certificates of Analysis with batch-specific purity data
-
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
-
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
-
Expert Technical Support: Knowledgeable staff for reconstitution and protocol guidance
-
Secure, Discreet Packaging: Temperature-appropriate shipping containers
-
EU Sourced: Manufactured and distributed from within the European Union
Frequently Asked Questions
Q: Is the GHRP-2 + Mod GRF 1-29 blend suitable for human consumption?
A: No. This peptide blend is strictly for research and laboratory use only . It is not for human or animal consumption, and must not be used for therapeutic, diagnostic, or clinical applications. These peptides are investigational compounds not approved by regulatory bodies like the FDA, EMA, or MHRA for any therapeutic indication; all use is considered experimental. Researchers must handle these compounds in accordance with institutional safety guidelines and local regulations.
Q: What purity level can I expect when I buy this blend from eupeptidelap.co.uk?
A: All GHRP-2 + Mod GRF 1-29 blend from eupeptidelap.co.uk is HPLC-verified at ≥99% purity . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.
Q: How should I store this peptide blend for long-term stability?
A: Store the lyophilized blend at −20°C in a dry, dark environment . Prior to reconstitution, allow the vial and solvent to reach ambient laboratory temperature. For longer-term storage (several months to years), store peptides in a freezer at -20°C or -80°C. Once peptides have been received, it is imperative that they are kept cold and away from light.
Q: What is the recommended reconstitution protocol for this blend?
A: Reconstitute using bacteriostatic water or another suitable solvent according to your research protocol. Gently swirl—not shake—to dissolve the lyophilized powder completely. Once reconstituted, peptides must be stored in the refrigerator and will remain stable for up to 30 days .
Q: What is the mechanism of action of GHRP-2?
A: GHRP-2 is a growth hormone secretagogue receptor (GHS-R) agonist that stimulates GH release through several pathways, including cAMP pathway activation, calcium channel modulation, and protein kinase C signaling . Unlike GHRP-6, GHRP-2 increases intracellular cAMP concentrations in somatotroph cells in a manner similar to GRF . The effect of maximal doses of GHRP-2 (100 nM) on GH release can be totally abolished by a specific GRF receptor antagonist .
Q: What is the mechanism of action of Mod GRF 1-29?
A: Mod GRF 1-29 is a synthetic analog of GHRH that binds to GHRH receptors on pituitary somatotroph cells. It activates G-proteins, leading to cAMP production and protein kinase activation, which influences gene expression for GH synthesis. Its structural modifications increase resistance to enzymatic degradation, allowing for more impactful receptor engagement and longevity within experimental systems .
Q: What research areas commonly use this peptide blend?
A: This blend is widely used in growth hormone signaling research , appetite and metabolic studies , growth regulation research , age-related endocrine investigations , tissue regeneration studies , cellular metabolism and adipose tissue research , and cognitive and neural research .
Q: How does GHRP-2 compare to GHRP-6 in terms of potency?
A: Dose-response relationships indicate that GHRP-2 has similar potency to GRF and is approximately 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1) tested in the same experimental systems .
Q: Do you ship this peptide blend to EU countries?
A: Yes. As a dedicated EU peptide supplier, we ship the GHRP-2 + Mod GRF 1-29 blend to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.
Q: What documentation do you provide with this blend orders?
A: Every order includes a Certificate of Analysis with batch-specific purity data. Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification.
Q: Does GHRP-2 cause cross-desensitization with GRF?
A: No. Research demonstrates that when GHRP-2 is applied first and GRF is given one hour later, the second response is not attenuated, indicating no cross-desensitization between GHRP-2 and GRF responses .
Q: Does GHRP-2 increase cAMP levels?
A: Yes. In partially purified sheep somatotrophs, GHRP-2 increased intracellular cAMP concentrations in a dose-dependent manner, similar to GRF . This distinguishes it from GHRP-6, which does not increase cAMP levels.
Q: Does a GRF receptor antagonist block GHRP-2 effects?
A: Yes. The effect of maximal doses of GHRP-2 (100 nM) on GH release is totally abolished by [Ac-Tyr1, D-Arg2] GRF 1-29 (1 μM), which is believed to be a specific antagonist for the GRF receptor . This same antagonist does not affect GH release induced by GHRP-6 .
Q: What is the EC₅₀ for GHRP-2-stimulated GH release?
A: Research indicates that GHRP-2 demonstrates similar potency to GRF in stimulating GH secretion, with dose-response relationships showing it is approximately 10-fold more potent than GHRP-6 .
Q: Does GHRP-2 affect appetite?
A: Studies suggest that GHRP-2 may influence appetite regulation. In controlled research, models introduced to the peptide displayed a 35% increase in food consumption compared to control groups, normalized based on body mass .
Q: Do you offer bulk quantities of this peptide blend for institutional research?
A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs. ...........................................
Advance Your Research with GHRP-2 + Mod GRF 1-29 Blend
eupeptidelap.co.uk is your trusted source for the GHRP-2 30mg + Mod GRF 1-29 30mg peptide blend, the premium choice for researchers investigating growth hormone dynamics, appetite regulation, metabolic pathways, and tissue regeneration. With well-characterized mechanisms, complementary receptor targeting, and GHRP-2’s unique cAMP-activating profile that distinguishes it from other GHRP family members, this blend represents a sophisticated tool for exploring the complex biology of the GH axis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Whether you are exploring appetite regulation, designing metabolic studies, investigating age-related endocrine changes, or researching tissue repair mechanisms, our rigorously tested blend provides the quality and consistency your work demands.
Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.
